However, people are often priced out of proven life-saving or life-altering treatments, as health insurance companies and pharmaceutical labs deploy disinformation and lawfare, instrumentalizing the FDA’s regulation mandate to maximize profits. Also, many promising products are not accessible through regulated channels, stuck in long regulatory approval processes or abandoned for lack of commercial appeal.
Alternative distribution is a confusing ecosystem, with a complex web of manufacturers, suppliers, distributors, and other middlemen which are all in constant flux as businesses shut down and restart under a new name. The FDA is not ensuring the safety of these supply chains, and the result is a lack of reputable, stable sources.
When individuals opt out of FDA-regulated channels — either by obtaining regulated products from unregulated sources, or by purchasing products that are altogether unregulated — they take significant risk: products not matching the label, wrong dosage, contamination, and a complete lack of recourse.
And yet, the market for these chemicals is surprisingly large and growing.
Finnrick’s mission is to make sovereign health safer by forcing transparency and accountability in these supply chains. Finnrick maintains a public ranking of vendors based on the testing of collaboratively-sourced samples. This ranking promotes vendors that deliver consistently good quality and implement good practices, while naming and shaming the worst performers to drive them out of the market.